CN1131870C - 新的吡咯磺酰胺化合物 - Google Patents

新的吡咯磺酰胺化合物 Download PDF

Info

Publication number
CN1131870C
CN1131870C CN988028867A CN98802886A CN1131870C CN 1131870 C CN1131870 C CN 1131870C CN 988028867 A CN988028867 A CN 988028867A CN 98802886 A CN98802886 A CN 98802886A CN 1131870 C CN1131870 C CN 1131870C
Authority
CN
China
Prior art keywords
compound
formula
salt
group
definition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN988028867A
Other languages
English (en)
Chinese (zh)
Other versions
CN1261366A (zh
Inventor
水野章
柴田诚
龟位智惠
深见治一
猪俣则夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asubio Pharma Co Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Publication of CN1261366A publication Critical patent/CN1261366A/zh
Application granted granted Critical
Publication of CN1131870C publication Critical patent/CN1131870C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN988028867A 1997-12-26 1998-12-25 新的吡咯磺酰胺化合物 Expired - Fee Related CN1131870C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP366757/1997 1997-12-26
JP9366757A JPH11193290A (ja) 1997-12-26 1997-12-26 ピロールスルホンアミド系化合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB031328490A Division CN1193014C (zh) 1997-12-26 1998-12-25 新的吡咯磺酰胺化合物

Publications (2)

Publication Number Publication Date
CN1261366A CN1261366A (zh) 2000-07-26
CN1131870C true CN1131870C (zh) 2003-12-24

Family

ID=18487596

Family Applications (2)

Application Number Title Priority Date Filing Date
CN988028867A Expired - Fee Related CN1131870C (zh) 1997-12-26 1998-12-25 新的吡咯磺酰胺化合物
CNB031328490A Expired - Fee Related CN1193014C (zh) 1997-12-26 1998-12-25 新的吡咯磺酰胺化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB031328490A Expired - Fee Related CN1193014C (zh) 1997-12-26 1998-12-25 新的吡咯磺酰胺化合物

Country Status (9)

Country Link
US (3) US6331623B1 (enExample)
EP (1) EP0970089A2 (enExample)
JP (1) JPH11193290A (enExample)
KR (1) KR20000075642A (enExample)
CN (2) CN1131870C (enExample)
AU (1) AU752510B2 (enExample)
CA (1) CA2282815A1 (enExample)
HU (1) HUP0001183A3 (enExample)
WO (1) WO1999033841A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11193289A (ja) * 1997-12-26 1999-07-21 Suntory Ltd ピロールスルホンアミド誘導体
JPH11193290A (ja) * 1997-12-26 1999-07-21 Suntory Ltd ピロールスルホンアミド系化合物
US10556013B2 (en) 2017-06-20 2020-02-11 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
EP4497474A3 (en) 2018-10-17 2025-04-23 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3198117B2 (ja) 1990-02-07 2001-08-13 サントリー株式会社 ピロロアゼピン誘導体
FR2675802B1 (fr) * 1991-04-26 1993-12-24 Rhone Poulenc Rorer Sa Antiserotonines, leur preparation et les medicaments les contenant.
EP0551527B8 (en) * 1991-08-07 2003-08-13 Daiichi Suntory Pharma Co., Ltd. Pyrroloazepine derivative
DE69232981T2 (de) * 1991-08-07 2004-01-08 Daiichi Suntory Pharma Co., Ltd. Pyrroloazepinverbindungen
AU690622B2 (en) * 1993-12-24 1998-04-30 Daiichi Suntory Pharma Co., Ltd Benzothiazine derivative
ATE251135T1 (de) 1995-11-02 2003-10-15 Daiichi Suntory Pharma Co Ltd Verfahren zur herstellung von 1-substituierten pyrrol-3-carbonsäure-derivaten
DE69620745T2 (de) 1995-12-01 2002-10-31 Suntory Limited, Osaka Pyrroloazepin-derivate
JPH10251258A (ja) 1997-03-14 1998-09-22 Suntory Ltd ピロロアゼピン系化合物
JPH11193289A (ja) 1997-12-26 1999-07-21 Suntory Ltd ピロールスルホンアミド誘導体
JPH11193290A (ja) * 1997-12-26 1999-07-21 Suntory Ltd ピロールスルホンアミド系化合物
IL139064A0 (en) 1999-02-17 2001-11-25 Suntory Ltd Intermittent claudication therapeutic drugs comprising pyrroloazepines

Also Published As

Publication number Publication date
KR20000075642A (ko) 2000-12-26
US20030229070A1 (en) 2003-12-11
JPH11193290A (ja) 1999-07-21
CN1261366A (zh) 2000-07-26
WO1999033841A3 (en) 1999-09-02
US6583296B2 (en) 2003-06-24
AU752510B2 (en) 2002-09-19
HUP0001183A2 (hu) 2000-10-28
AU1690799A (en) 1999-07-19
WO1999033841A2 (en) 1999-07-08
HUP0001183A3 (en) 2002-12-28
US20020137928A1 (en) 2002-09-26
US6743913B2 (en) 2004-06-01
CN1193014C (zh) 2005-03-16
EP0970089A2 (en) 2000-01-12
WO1999033841B1 (en) 2001-05-25
CN1495163A (zh) 2004-05-12
CA2282815A1 (en) 1999-07-08
US6331623B1 (en) 2001-12-18

Similar Documents

Publication Publication Date Title
CN1160330C (zh) N-取代2-氰基吡咯烷类化合物
KR100621287B1 (ko) 신경 펩타이드 ｙ 수용체에 대한 리간드로서의 퀴놀린유도체
JPH10511687A (ja) グリコーゲンホスホリラーゼ抑制剤としての置換されたｎ−（インドール−２−カルボニル）−グリシンアミド類および誘導体
WO2001025228A1 (en) Amine derivatives
EP1341782A2 (en) Inhibitors of p38 kinase
KR100885104B1 (ko) 아자비시클릭 유도체, 이의 제조 방법 및 이를 함유하는약제 조성물
CN1059722A (zh) 3-芳基-4(3h)喹唑酮类肠促胰酶肽拮抗剂及其药物制剂
JP4076234B2 (ja) テトラヒドロベンズインドール化合物
CN1131870C (zh) 新的吡咯磺酰胺化合物
EA004925B1 (ru) 2-(1h-индол-3-ил)-2-оксоацетамиды, обладающие противоопухолевой активностью
WO2006078006A1 (ja) インドール類およびそれを含む医薬組成物
JPWO1998000400A1 (ja) テトラヒドロベンズインドール化合物
JP3563076B2 (ja) ピロロアゼピン誘導体
CN1063177C (zh) 治疗偏头痛的吲哚烷基－吡啶基和嘧啶基哌嗪的1,2,5－噻二唑衍生物
JPWO1997020845A1 (ja) ピロロアゼピン誘導体
CN1260798A (zh) 具有5－羟色胺－2受体拮抗作用和α1－阻断作用的吡咯噻嗪和吡咯硫杂吖庚因化合物
WO2000005206A1 (en) Arylpiperazine derivatives useful as uro-selective alpha-1-adrenoceptor blockers
CN1094126C (zh) 吡咯并吖庚因化合物
TW201410649A (zh) 吲哚衍生物及該吲哚衍生物在藥理學上可容許之鹽
BG109767A (bg) Пиридинови производни на алкил оксиндоли като 5-нт7 рецепторни активни агенти
MXPA06013766A (es) Composicion para el control del dolor neuropatico.
CN1087632A (zh) 1，3，4-苯并三氮杂䓬-5(4h)-酮衍生物及其制备方法
EP1097134A1 (en) Arylpiperazine derivatives useful as uroselective alpha1-adrenoceptor blockers
JPH0641071A (ja) インドール酢酸エステル誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: SUNTORY LTD

Free format text: FORMER OWNER: SUNTORY LTD.

Effective date: 20030418

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20030418

Address after: Tokyo, Japan

Applicant after: Daiichi Suntory Pharma Co., Ltd.

Address before: Osaka

Applicant before: Suntory Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: THE FIRST ASHBIAO PHARMACEUTICAL CO., LTD.

Free format text: FORMER NAME OR ADDRESS: SUNTORY LTD

CP01 Change in the name or title of a patent holder

Address after: Tokyo, Japan

Patentee after: Daiichi Asubio Pharma Co., Ltd.

Address before: Tokyo, Japan

Patentee before: Daiichi Suntory Pharma Co., Ltd.

C56 Change in the name or address of the patentee

Owner name: ASTERIX PHARMACEUTICAL CO., LTD.

Free format text: FORMER NAME OR ADDRESS: THE FIRST ASHBIAO PHARMACEUTICAL CO., LTD.

CP01 Change in the name or title of a patent holder

Address after: Tokyo, Japan

Patentee after: Asubio Pharma Co., Ltd.

Address before: Tokyo, Japan

Patentee before: Daiichi Asubio Pharma Co., Ltd.

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee